7-hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines

被引:1
|
作者
Xiao, HH
Makeyev, Y
Butler, J
Vikram, B
Franklin, WA
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA
[2] Yeshiva Univ Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10461 USA
关键词
D O I
10.1667/0033-7587(2002)158[0084:HUPSCW]2.0.CO;2
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Mutations in TP53 occur in more than 50% of the lung cancer patients and are associated with an increased resistance to chemotherapy and radiotherapy. The human lung adenocarcinoma cell lines A549 and LXSN contain a wild-type TP53 and were growth arrested at both the G(1)- and G(2)-phase checkpoints after irradiation. However, a TP53-disrupted cell line, E6, was arrested only at the G(2)-phase checkpoint. UCN-01 (7-hydroxystaurosporine), a CHEK1 inhibitor that abrogates the G(2) block, has been reported to enhance radiation toxicity in human lymphoma and colon cancer cell lines. In this study, UCN-01 preferentially enhanced the radiosensitivity of the TP53-disrupted E6 cells compared to the TP53 wildtype cells. This effect was more pronounced in cells synchronized in early G(1) phase, where the E6 cells showed a higher resistance to radiation in the absence of drug. These results indicate that the combination of UCN-01 and radiation can more specifically target resistant TP53 mutated cancer cells and spare TP53 wild-type normal cells. (C) 2002 by Radiation Research Society.
引用
收藏
页码:84 / 93
页数:10
相关论文
共 38 条
  • [21] Potentiation of 1-β-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing Bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01)
    Tang, L
    Boise, LH
    Dent, P
    Grant, S
    BIOCHEMICAL PHARMACOLOGY, 2000, 60 (10) : 1445 - 1456
  • [22] Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-O1) in human cancer cell lines, possibly influenced by p53 function
    Shao, RG
    Cao, CX
    Shimizu, T
    OConnor, PM
    Kohn, KW
    Pommier, Y
    CANCER RESEARCH, 1997, 57 (18) : 4029 - 4035
  • [23] UCN-01 synergizes with cisplatin (CDDP) in non-small cell lung carcinoma (NSCLC) cell lines with wild-type and mutant RB and p53.
    Mack, PC
    Edelman, MJ
    Gandara, DR
    Gumerlock, PH
    JOURNAL OF INVESTIGATIVE MEDICINE, 1998, 46 (01) : 126A - 126A
  • [24] TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin
    Hinz, Trista K.
    Kalkur, Roshni
    Rabinovitch, Jonathan
    Hinkle, Wyatt
    Heasley, Lynn E.
    MOLECULAR PHARMACOLOGY, 2021, 100 (02) : 144 - 154
  • [25] The influence of p53 transactivation and repression functions on abrogation of DNA damage-induced cell cycle arrest by UCN-01 in breast cancer cells.
    Kohn, EA
    Bresnick, E
    Direnzo, J
    Eastman, A
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6220S - 6220S
  • [26] Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation
    Paolo Fiorentino, Francesco
    Tokgun, Elvan
    Sole-Sanchez, Sonia
    Giampaolo, Sabrina
    Tokgun, Onur
    Jauset, Toni
    Kohno, Takashi
    Perucho, Manuel
    Soucek, Laura
    Yokota, Jun
    ONCOTARGET, 2016, 7 (21) : 31014 - 31028
  • [27] PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53
    Liu, Qi
    Gheorghiu, Liliana
    Drumm, Michael
    Clayman, Rebecca
    Eidelman, Alec
    Wszolek, Matthew F.
    Olumi, Aria
    Feldman, Adam
    Wang, Meng
    Marcar, Lynnette
    Citrin, Deborah E.
    Wu, Chin-Lee
    Benes, Cyril H.
    Efstathiou, Jason A.
    Willers, Henning
    ONCOGENE, 2018, 37 (21) : 2793 - 2805
  • [28] WEE1 kinase inhibitor MK-1775 sensitizes oral tongue squamous cell carcinoma cells to radiation irrespective of TP53 status
    Al-Jamaei, Aisha Hussein
    de Visscher, Jan G. A. M.
    Subramanyam, V. Ramadugula
    Forouzanfar, Tymour
    Sminia, Peter
    Doulabi, Behrouz Zandieh
    Helder, Marco N.
    ORAL DISEASES, 2023, 29 (07) : 2640 - 2649
  • [29] Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: Effect of TP53 or hMLH1 deficiency
    Kennedy, AS
    Harrison, GH
    Mansfield, CM
    Zhou, XJ
    Xu, JF
    Balcer-Kubiczek, EK
    INTERNATIONAL JOURNAL OF CANCER, 2000, 90 (04) : 175 - 185
  • [30] Association of Wild-Type TP53 with Downregulation of Lovastatin Sensitivity in Human Non-Small Cell Lung Cancer Cells
    Chang, Yu-Yao
    Yang, Tsung-Ying
    Sheu, Gwo-Tarng
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (09) : 10130 - 10139